

Preferred Provider Network

- **March 24, 2021**



HONORHEALTH®

COLLABORATING FOR CARE


Innovation Care Partners & HonorHealth – Confidential Information

As of 03/24/2021

Agenda

- Overview of COVID-19 statistics
- Arizona progress with COVID-19
- Updates from CMS, and Community
- Updates from HonorHealth
- Guest speaker

Johns Hopkins Tracker




As of 3/22/2021

CORONAVIRUS STATUS 3/22/2021


- **World** 123 million cases, 2.71 million deaths
- **US** 29.8 million cases, 542k deaths
- **Arizona** 836k cases, 16,742 deaths

7 Day Average for Maricopa County


1. Cases # -84.63% (17.4 per 100k)
2. Deaths # -13.56% (2.27 per 100k)
3. % Positivity # -0.35% (4.03)
4. Testing Vol # -11.66% (1627.52 per 100k)
5. New COVID admits # -17.00% (293)



United States Forecasting



ED Visits by Syndrome in United States




- **Coronavirus like illness (CLI) or a COVID-19 diagnostic code**
- **Influenza like illness (ILI without mention of specific influenza)**
- **Pneumonia**
- **Shortness of breath**

As of 3/22/21

Arizona Daily Case Counts

COVID-19 Cases by Age Group




Number of Cases

836,737

Select a county to filter the other graphs.

Graphs will not be displayed for counties with fewer than 10 cases.



As of 3/22/2021

Arizona COVID-19 Deaths


COVID-19 Deaths (total)

16,745

65+: 12,547


COVID-19 Deaths by County

Data will not be shown for counties with fewer than three deaths.



COVID-19 Deaths by Gender

COVID-19 Deaths by Date of Death



Recent deaths may not be reported yet. Cases missing the date of death are excluded from the graph above, but are included in all other numbers.

COVID-19 Deaths by Age Group

COVID-19 Deaths by Race/Ethnicity


Date 3/22/21

% Positive Diagnostic Tests Increasing


As of 3/22/2021

People tested using **All** tests by county

Select a county to filter the data.



People tested using **All** tests by date of collection




People tested using **All** Testing by Age Group

Less than 20 years	719,253
20 - 44 years	1,779,574
45 - 54 years	602,219
55 - 64 years	581,189
65 years and older	744,587
Unknown	10,220

■ People tested for COVID-19 and ■ percent positive by week

Percent positive is the number of people with a positive result in Electronic Laboratory Reporting (ELR), out of all people with COVID-19 testing reported via ELR in AZ. Diagnostic tests include PCR


Total % Positive COVID-19 **Diagnostic** Tests: **14.0%**



Date Updated:

3/22/2021


Total % Positive COVID-19 **Serology** Tests: **12.8%**



*NOTE: Results from the last 4-7 days may not be reported yet.

As of 3/22/2021

ICU Beds in Use in Arizona



COVID-19 in the 771 Long-Term Care Facilities

*Long-term care facilities include nursing homes, assisted living facilities, and hospices. As of 7/17/20 this no longer includes other congregate settings.


Of 8,146 COVID-19 cases among residents, **2,270 (28%)** have been hospitalized and **2,124 (26%)** have died.



Of 5,790 COVID-19 cases among staff, **239 (4%)** have been hospitalized and **16 (0%)** have died.

As of 3/22/2021

Confirmed COVID-19 Rate per 1,000 in **Nursing Homes – USA**




Confirmed COVID-19 Rate per 1,000 in Nursing Homes – AZ


Week Ending* March 14, 2021
 Count of Resident COVID-19 Cases 26
 Rate of Resident COVID-19 Cases 2.66

Display by State
 AZ

Display by
 All



Confirmed COVID-19 Rate per 1,000 in **Nursing Homes STAFF** – AZ



NEWS UPDATES



03/24/2021

Major European Nations Suspend Use of AstraZeneca Vaccine

- Germany, France, Italy, Spain, and others suspended use over reports of blood clots out of an abundance of caution
- EU's drug regulatory agency called for meeting to review findings
- 37 reports of blood clots out of more than 17 million people vaccinated in the 27-country EU and Britain, lower rate than expected in general population
- 7 cases of cerebral vein thrombosis in 1.6m vaccinations in Germany
- AstraZeneca, WHO, and EU's European Medicines Agency reports no evidence of increased risk

As of 03/16/2021

Italy Prepares For Another Lockdown

- 3rd lockdown since the start of the pandemic, affects $\frac{3}{4}$ of the population
- Triggered by a spike in cases, likely due to UK variant
- In effect through April 6th
 - All schools, restaurants, shops and museums are closed
 - Stay at home order except for work, health or essential reasons
- ICU bed capacity in Paris is maxed, patients being transferred out of the city for care. No current lockdown for France.

As of 03/16/2021

COVID Antibodies Detected in Blood Donations

- American Red Cross reports that 1 in 5 blood donations from unvaccinated patients tested positive for COVID-19 antibodies
- Antibodies don't necessarily correlate with immunity
- % of asymptomatic donor positivity increased temporally with spike in cases
- 9% of population has tested positive for COVID infection (JHU Tracker), but CDC estimates actual cases are closer to 20-25%, which aligns with Red Cross findings

Vaccination-Induced Antibodies During Pregnancy

- 1st case of COVID-19 antibodies passed to child through birth was reported.
- Antibodies detected in an infant (cord blood) born to a mother who received her first dose of the Moderna vaccine three weeks before giving birth.
- Further studies have to determine how long this protection will last, and what level of protection it confers.

T-Cell Testing for Past Infection

- FDA issued EUA for the T-Detect COVID Test (Adaptive Biotechnologies)
- Analyzes DNA sequences from T cells (WBC's) to identify Pt's with an adaptive T cell immune response to SARS-CoV-2, indicating recent or previous infection.
- Negative results do not preclude acute/current infection and should not be used to diagnose current infection.
- Unknown how long the T cell immune response remains following infection, or what level of protection it provides.
- It is thought to detect past infection over greater periods of time than current antibody tests.

As of 03/17/2021

Modified Moderna Vaccines/Regimens

New Phase 1 Studies have started:

- **Ancestral (Original)= mRNA-1273**
 - Studying 3rd dose of same vaccine as a booster
- **Modified= mRNA-1273.351**
 - Single dose as booster vs.
 - Combination of Ancestral+Modified as multivalent option (mRNA-1273.211)
- **Next-Generation= mRNA-1283**
 - Potential to be shipped and stored in refrigerator instead of freezer
 - Single dose vs. double dose initially, will look at booster effectiveness later
- **Seronegative Option**
 - 1st shot: Modified 1273.351
 - 2nd shot: Multivalent 1273.211


As of 03/16/2021

Nurses Account for Most COVID-19 Deaths in Healthcare Workers

- 3,561 known U.S. healthcare worker COVID-19 deaths as of March 17


Deaths by occupation:

- **Nurse: 32 percent** of all known HC staff COVID-19 deaths
- **Healthcare support: 20 percent**
- **Physician: 17 percent**
- **Medical first responder: 7 percent**
- **Admin/admin support: 6 percent**
- **Diagnosing clinician: 4 percent**
- **Healthcare technologist: 4 percent**
- **Community or social worker: 3 percent**
- **Cleaner: 2 percent**
- **Other: 2 percent**
- **Security personnel: 1 percent**
- **Culinary/food services: 1 percent**
- **Coroner: 0 percent**



Eli Lilly monoclonal Ab Cuts Events by 87%

- Bamlanivimab and etesevimab
- BLAZE-1 phase 3 cohort of 769 mild-to-mod patients age 12+ at high risk for progressing to severe disease
- 15 events (hospitalizations or deaths) in placebo
- 4 events in treatment group




As of 03/16/2021

How Do We Think Vaccines Will Change Things?

Fig. 1: Perspectives on How Vaccinations Will Change Things

Share of adults who said getting a COVID-19 vaccine would make them feel **more comfortable** or **have no impact on their comfort level** with the following activities:



As of 03/16/2021

Source: Morning Consult

4 Potential New COVID-19 Therapeutics

- Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program
- ACTIV-2 randomized, placebo-controlled study of non-hospitalized adults with mild to moderate COVID-19 symptoms:
 - SNG001 – inhalable beta interferon delivered by nebulizer (Synairgen)
 - AZD7442 – long-acting monoclonal antibody combination both infusion and IM injection (AstraZeneca)
 - Cameostat mesylate – oral protease inhibitor that may block SARS-CoV-2 from entering cells (Sagent pharmaceuticals)

As of 03/10/2021

LONG COVID SYNDROME

HonorHealth Library Long COVID page

HONORHEALTH™

Long COVID: Welcome!

Welcome! ▾

Long COVID



In the News




Diagnosis



*Patient & Practice
Management*



Placeholder



Information for Patients

Long COVID: What is it?

The body of information about "Long COVID," (also called "post-COVID syndrome," or "Long-haul COVID") is growing rapidly, as the [CDC has noted](#). We expect the information in this guide will change frequently.

- It is estimated that 10% to 15% of COVID-19 survivors experience persistent symptoms.
- Currently patient management is symptomatic, as we await evidence-based guidelines.
- [Patients, support groups](#), and researchers are gathering the stories of persons with the symptoms we associate with the long-term effects of SARS.
- In addition to this guide, HonorHealth librarians have created an [extensive resource collection for COVID-19](#), including a [special tab for long-covid articles](#).

Definitions / Overview

Long covid: diagnosis, management, prognosis (1:13:55)

Persistent symptoms ([MMWR](#))

- Fatigue

<https://azhin.org/longcovid>

As of 03/10/2021

PASC – Post-Acute Sequelae of SARS-CoV-2

- Long COVID = Long Haulers = PASC
- NIH launches new study hoping to answer:
 - Spectrum of recovery
 - Underlying biological cause of these prolonged symptoms
 - Vulnerabilities
 - Does SARS-CoV-2 infection trigger changes in the body that increase the risk of other conditions, such as chronic heart or brain disorders?


As of 03/17/2021

Long Covid Syndrome Survey

- 3,700 studied in 56 countries
- Most couldn't work full time 6 months after Covid
- Most common symptoms
 - **Fatigue 77%, post-exertional malaise 72%, and cognitive dysfunction 55%**
- More severely ill patients had increased risk of pulmonary diffusion abnormality, fatigue or muscle weakness, anxiety or depression
- Recent media coverage has highlighted stories of long-haul COVID patients recovering post-vaccination. No data to support this but helps to drive hypotheses and research.

As of 03/17/2021

Symptom Time Courses PCR vs. Antibody Tests



As of 03/18/2021

VARIANTS UPDATES

As of 03/24/2021

Covid-19 Variant Surveillance in Arizona

- TGen North – non-profit laboratory partner, one of the labs working on genetic surveillance of SARS-CoV-2
- Arizona SARS-CoV-2 Sequencing Dashboard for Tgen:
 - <https://pathogen.tgen.org/covidseq-tracker/>
- In Arizona:
 - 17% CAL.20C
 - 1.5% UK variant
 - 0.1% Brazil variant
 - 0% South Africa variants

As of 03/17/2021

TGen Variant Dashboard - Arizona



Arizona COVID-19 Sequencing Dashboard


Total Genomes: 9,740

Number of Genomes Since December: 3,755

Variants of Concern (VOC)

Number of Genomes Sequenced December - Present
Hover over the bars to view proportions.

Variant Name (Origin)



Variants of Interest (VOI)

Number of Genomes Sequenced December - Present

Variant Name (Origin)



Mutations of Interest

Number of Genomes Sequenced December - Present

Mutation



Description of Mutations of Interest

The mutations shown on the graph to the left are all in the "S" or spike protein of SARS-CoV-2.

The 501Y mutation has been associated with increased ACE2 receptor binding.

The 484K mutation has been associated with reduced antibody binding and immune escape.

The 452R mutation has been associated with increased transmissibility, infectivity, and potentially impacts effectiveness of some clinical treatments.

The 417N/T mutation has been associated with immune evasion.

As of 03/23/2021

Variants in the US

Variant	Reported Cases in US	Number of Jurisdiction with ≥1 Case Reported
B.1.1.7	5,576	51
B.1.351	180	26
P.1	48	15


As of 3/23/2021

Arizona

B.1.1.7 Variant: 62

P.1. Variant: 4

B.1.351 Variant: 0



Emerging Variants in Arizona

First cases of Brazilian COVID-19 variant detected in Arizona

BY KTAR.COM | MARCH 12, 2021 AT 5:30 PM
UPDATED: MARCH 12, 2021 AT 5:41 PM


Share



(Photo by George Frey/Getty Images)

First Cases Of Brazilian COVID-19 Variant Detected In Arizona

March 13, 2021 ADI Staff Reporter



COVID -19, commonly known as coronavirus [Slide courtesy CDC]



PHOENIX – On Friday, the Arizona Department of Health Services, the Yuma County Public Health Services District, and Translational Genomics Institute (TGen) reported that the P1 COVID-19 mutation, commonly referred to as the Brazilian variant, has been confirmed in three test samples from the state.

As of 03/16/2021

PUBLIC HEALTH UPDATES

As of 03/24/2021

CMS Updates Nursing Home Guidance

- Starting March 10, 2021, the following visitation guidance recommends:
- **Indoor Visitation**
- Facilities should allow responsible indoor visitation at all times and for all residents, regardless of vaccination status of the resident, or visitor, unless certain scenarios arise that would limit visitation for:
 - Unvaccinated residents if; 1) the COVID-19 county positivity rate is greater than 10 percent; and 2) less than 70 percent of residents in the facility are fully vaccinated

CMS Updates Nursing Home Guidance

- **Indoor Visitation**

- Certain scenarios arise that would limit visitation for:
 - Residents with confirmed COVID-19 infection, whether vaccinated or unvaccinated, until they have met the criteria to discontinue transmission-based precautions; or
 - Residents in quarantine, whether vaccinated or unvaccinated, until they have met criteria for release from quarantine.

CMS Updates Nursing Home Guidance

- **Indoor Visitation During an Outbreak**
- While outbreaks increase the risk of COVID-19 transmission, a facility should not restrict visitation for all residents as long as there is evidence that the transmission of COVID-19 is contained to a single area (e.g., unit) of the facility.
 - Facilities should continue to adhere to CMS regulations and guidance for *COVID-19 testing*, including routine staff testing, testing of individuals with symptoms, and outbreak testing

CMS Updates Nursing Home Guidance

• Indoor Visitation During an Outbreak

- When a new case of COVID-19 among residents or staff is identified, a facility should immediately begin outbreak testing and suspend all visitation until at least one round of facility-wide testing is completed.
- Visitation can resume based on the following criteria:
 - If the first round of outbreak testing reveals no additional COVID-19 cases in other areas (e.g., units) of the facility, then visitation can resume for residents in areas/units with no COVID-19 cases. However, the facility should suspend visitation on the affected unit until the facility meets the criteria to discontinue outbreak testing.
 - If the first round of outbreak testing reveals one or more additional COVID-19 cases in other areas/units of the facility (e.g., new cases in two or more units), then facilities should suspend visitation for all residents (vaccinated and unvaccinated), until the facility meets the criteria to discontinue outbreak testing.

CMS Updates Nursing Home Guidance

- **Compassionate Care Visits**

- Visits for compassionate care, such as an end-of-life situation or a residents in decline or distress should be allowed at all times for any resident (vaccinated or unvaccinated), regardless of the above scenarios. In addition, facilities and visitors should continue all infection prevention and control practices.

- **Other CMS instructions**

- Visitors should not be required to be tested or vaccinated (or show proof of such) as a condition of visitation.
- Federal and state surveyors are not required to be vaccinated and must be permitted entry into facilities unless signs or symptoms of COVID-19 are present.

As of 3/23/2021

NEW CDC Guidance for Vaccinated People

- A person is fully vaccinated if:
 - They **completed a COVID-19 vaccine series at least 2 weeks ago**
 - For a 2-dose series (Pfizer, Moderna) this means 2 weeks after the 2nd dose
 - For a 1-dose series (Johnson & Johnson/Janssen), this means 2 weeks after the 1st/only dose
- Now people who are fully vaccinated:
 - Can **visit with other fully vaccinated people indoors** in non-healthcare settings **without wearing masks** or practicing physical distancing
 - Can **visit with unvaccinated people from one additional household** who are not at high risk for severe illness from COVID-19 indoors in non-healthcare settings **without wearing masks** or practicing physical distancing

As of 3/23/2021

NEW CDC Guidance for Vaccinated People

- Fully vaccinated people:
 - Do not need to quarantine at home or get tested for COVID-19 after a known exposure to COVID-19 as long as they do not have any symptoms consistent with COVID-19 and do not live in a healthcare or congregate setting
 - ***removed the 90-day restriction**
 - If fully vaccinated person develops symptoms, stay home, isolate, seek testing
 - Congregate settings: hospitals, hospice facilities, SNFs, ALF, group homes, inpatient physical/addiction rehab facilities, shelters with dormitory facilities, temporary shelters, jails, detention facilities

As of 3/23/2021

NEW CDC Guidance for Vaccinated People


- People who are fully vaccinated should continue to:
 - Wear a well-fitting mask, physically distance, adhere to other prevention measures when:
 - In public.
 - Around unvaccinated people from more than one household.
 - Visiting with unvaccinated people who are at increased risk for severe illness from COVID-19.
 - Visiting with unvaccinated people who have an unvaccinated household member who is at increased risk for severe illness from COVID-19.
 - Avoid medium- or large-sized in-person gatherings.
 - Get tested for COVID-19 if they have any symptoms consistent with COVID-19.
 - Follow all guidance issued by their employer.
 - Follow CDC and health department travel requirements and recommendations.

As of 3/23/2021

UPDATED Quarantine Guidance removes 90-day window to be considered fully vaccinated

<https://www.maricopa.gov/5491/Healthcare-Providers>

As of 03/23/2021



Operating Schools During COVID-19 – March 19th

- Revised physical distancing recommendations to reflect at **least 3 feet between students** in classrooms and provide clearer guidance when a greater distance (such as 6 feet) is recommended.
- Clarified that ventilation is a component of strategies to clean and maintain healthy facilities.
- Removed recommendation for physical barriers.

<https://www.cdc.gov/coronavirus/2019-ncov/community/schools-childcare/schools.html>

VACCINE UPDATES



As of 03/24/2021

Moderna Vaccination for Children

- Moderna to start clinical trials in children 6mo-11yo in Phoenix and other select cities
- Parents interested can go to [KidCOVE](#) site for eligibility information or can call 602-368-1928 or 866-913-5454.
- Will receive placebo or doses of 25, 50 or 100 micrograms of the vaccine – an adult dose is 100 – depending on their age.
- Expected capacity for 6,750 children

<https://connect.trialscope.com/studies/0e8fc8e6-5782-46fd-8b03-0994a5ad8b41>
<https://cronkitenews.azpbs.org/2021/03/16/phoenix-among-u-s-sites-for-modernas-covid-19-vaccine-trials-on-kids/>

Medicaid Vaccination Reimbursement

AHCCCS Plans will reimburse for COVID-19 Vaccines

- Initial vaccine administration - \$16.94
- Second vaccine administration - \$28.39
- Single dose vaccine administration - \$28.39
- Must be an ADHS On Boarded Provider
- Must be registered with AHCCCS
- Retroactive for Pfizer to 12/14/20, Moderna to 12/18/20 and Janssen to 02/27/21
- Exception: FQHC's, who are now receiving PPS Rate


Instructions:

- Do not bill for the vaccine itself
- Bill for admin fee using the NPI(s) of the ordering and rendering provider
- NDC not required but CPT codes are. They are specific to the manufacturer. See link below

Maricopa County aligning with AZDH

Arizona COVID-19 Vaccine Prioritization*

Age-Based Criteria**



Frontline Essential Workers°

MARCH 2021 - SUMMER 2021

- Food and agriculture
- Grocery store, convenience store, and carniceria workers
- U.S. Postal Service
- Manufacturing workers
- Public transit workers, including buses, Light Rail, Uber, Lyft, taxis, and rideshare
- State and local government workers
- Funeral home workers

Phase 1A & Prioritized 1B Groups

Vaccination will continue for groups previously listed under Phase 1A and Prioritized Phase 1B:

- Healthcare Workers & Healthcare Support Occupations
- Emergency Medical Services Workers
- Long-Term Care Facility Staff & Residents
- Education & Childcare Workers
- Protective Services Occupations
- Adults 65 and Older



*Distribution groups and timelines of phases shown are tentative. Local allocators may further subprioritize in each phase based on vaccine supply. This information is subject to change due to future vaccine distribution guidance recommendations, FDA approval of vaccines, and vaccine allocation/availability.

**Local jurisdictions may transition to a younger age group based on $\pm 55\%$ of current age group covered OR decreased demand in current group.


°Defined by ACIP as subset of essential workers at highest risk for work-related exposure due to required work-related duties performed onsite and involve being in close proximity (<6 feet) to public or coworkers. List may vary by local jurisdiction.

Revised March 1, 2021

Maricopa Vaccine Status

COVID-19 Vaccine Doses Administered to Maricopa County Residents

Doses administered are those that have gone into arms of Maricopa County residents at any vaccine administration site.




Maricopa County residents received 30,000 doses of vaccine per day
Almost 70% of those vaccinated in Maricopa County are 55 years or older.
For the age groups of 55 years and older:
72% of those 75+ have received at least one dose of vaccine.
65% of those 65-74 have received at least one dose of vaccine.
35% of those 55-64 have received at least one dose of vaccine.

Age Groups of People Fully Vaccinated in US

Age Group	Percentage	Count
<18	0.1	48,006
18-29	7.3	3,108,686
30-39	10	4,220,487
40-49	10.6	4,475,854
50-64	19.7	8,340,181
65-74	27.6	11,692,134
75+	24.6	10,418,196

As of 03/23/2021

Maricopa County Vaccine Map




As of 03/17/2021

<https://www.maricopa.gov/5659/COVID-19-Vaccine-Locations>

*The **BEST** vaccine is the vaccine you
can get!*

Global COVID-19 Vaccinations



U.S.

March 23


128M

doses given—enough for

19.7%

population coverage

Avg of **2.50M doses/day**
given



AZ – 37.1 doses per 100 people

US – 34.0 doses per 100 people

Note: Two doses are needed for full protection with the Pfizer and Moderna vaccines, while the J&J shot requires a single dose. Data from Bloomberg's Covid-19 Vaccine Tracker

AZ - 25% of population vaccinated

-> 14.6% fully vaccinated

-> 42.4% of 65+ pop fully vaccinated

Arizona

Total LTC Doses Administered: 121,343

People in LTC with at least One Dose: 80,659

People in LTC Fully Vaccinated: 40,192


As of 3/23/2021

MCDPH Johnson & Johnson Vaccine

- Distribution started the week of 3/10
- Vaccine prioritization for essential frontline workers
 - High risk as their work-related duties must be performed on-site and involve being within 6 feet of coworkers or members of the public
- Arizona's Vaccine and Antiviral Prioritization Advisory Committee (VAPAC) defines these essential workers:
 - Food and agriculture workers
 - Grocery store, convenience store, and carnicerias
 - U.S. Postal Service
 - Public Transit
 - State and local government
 - Funeral homes
 - Manufacturing
- MCDPH is partnering with groups to target these workers

As of 3/9/2021


Worldwide Vaccine Status



- FDA – gives EUA to Johnson & Johnson 2/27


- Pfizer/BioNtech
- Moderna
- Sputnik V - Russia
- Oxford/AstraZeneca – UK
- CanSinoBio - China
- Johnson & Johnson

Janssen (Johnson & Johnson) Vaccine












As of 03/16/2021

Side Effects by Vaccine – fewer with J&J



As of 03/16/2021

Operation Warp Speed EUA Tracker

Developer	Vaccine Candidate	Pre-Clinical	Phase 1	Phase 2	Phase 3	EUA Approval	Phase 3 Trial Results	Doses	Storage Requirement
J&J	JNJ-78436735	P1 Data Readout - Jan 13'21 (Positive)			P3 Trial Start Sept 3'20	Approved 2/27	66% * Phase 3 trial results from across eight countries and 44k+ volunteers		Standard Cold Chain
Astra Zeneca/Oxford	AZD1222	P1 Data Readout - Dec 8'20 (Flagged)			P3 Trial Start Aug 31'20	March/April		 	Standard Cold Chain
Novavax	NVX-CoV2373	P1 Data Readout - March '21			P3 Trial Start Dec 28'20	April/May	89.3% * Met primary endpoint in ongoing phase 3 UK trial	 	Standard Cold Chain
Sanofi Pasteur/GSK	SARS-CoV-2 Vaccine			P1/2 Trial Start Sept 3'20		End '21		 	Standard Cold Chain
Merck	V591		P1 Trial Start Sept'20			Discontinued 1/25/2021		 	Ultra Cold Chain

Novavax

- 96% effective against original ancestral coronavirus
- 86% effective against UK variant
- 55% effective in small South Africa trial on people without HIV, but still fully prevented severe illness (49% in HIV positive)
- Novavax is developing new formulations of vaccine against variants
- Expected to file for authorization in UK in 2nd quarter
- 30,000 person trial in US and Mexico results in April

Death rate 64% higher with UK Variant

- BMJ study published 3/10/21
- 54,906 matched pairs positive for COVID from 10/1 to 1/29/21
 - Of the total, 367 (0.3%) died
 - Of those with UK B1.1.7 variant, 227 (0.4%) died
 - Original strain had 141 (0.3%) deaths
- Hazard ratio for death by 28 days after diagnosis was 1.64 with UK variant, 1.32 for original
- Death rate not significantly higher up to 14 days after diagnosis, but rose days 15 to 28
- Caution: Absolute rates still low, study results not generalizable outside UK

**Original strain 2.5
deaths per 1,000**

**UK strain 4.1
deaths per 1,000**

HONORHEALTH UPDATES

As of 03/24/2021

HonorHealth Updates

Currently In Process:

- Guidelines for Post-Acute Liaisons to be able to return to hospitals.
- Post-Acute Network will be sent email with instructions when they are in effect.
- Coming in the next few weeks.



HonorHealth.com

GUEST SPEAKER

Southland

Welcome:

- Lori Passine *RN, BSN, MBA*
- Administrator
- lori.passine@chghospitals.com



Southland

Home Health • Hospice • Palliative Care • Mobile Physicians

A Cornerstone Healthcare Group Company

Questions – Type in Q & A Section

Post-Acute Website: <https://innovationcarepartners.com/postacutecommunications>



- If you have further questions or issues you would like to discuss
- Please contact:
Francisco Gonzalez– Preferred
Network & Clinical Development
Supervisor
fgonzalez@icphealth.com